Toll Free: 1-888-928-9744

Aerie Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Aerie Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Aerie Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Aerie Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aerie Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Aerie Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Aerie Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Aerie Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Aerie Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Aerie Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Aerie Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Aerie Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aerie Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Aerie Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Aerie Pharmaceuticals, Inc. Snapshot 4
Aerie Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Aerie Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Aerie Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Aerie Pharmaceuticals, Inc. - Pipeline Products Glance 10
Aerie Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Aerie Pharmaceuticals, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Aerie Pharmaceuticals, Inc. - Drug Profiles 12
(AR-13324 + latanoprost) 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
AR-13324 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AR-13533 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Aerie Pharmaceuticals, Inc. - Pipeline Analysis 15
Aerie Pharmaceuticals, Inc. - Pipeline Products by Target 15
Aerie Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 16
Aerie Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 17
Aerie Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 18
Aerie Pharmaceuticals, Inc. - Recent Pipeline Updates 19
Aerie Pharmaceuticals, Inc. - Dormant Projects 22
Aerie Pharmaceuticals, Inc. - Discontinued Pipeline Products 23
Discontinued Pipeline Product Profiles 23
(AR-12286 + travoprost) 23
AR-12286 23
Aerie Pharmaceuticals, Inc. - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26
List of Tables
Aerie Pharmaceuticals, Inc., Key Information 4
Aerie Pharmaceuticals, Inc., Key Facts 4
Aerie Pharmaceuticals, Inc. - Pipeline by Indication, 2014 6
Aerie Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 7
Aerie Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 8
Aerie Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 9
Aerie Pharmaceuticals, Inc. - Phase II, 2014 10
Aerie Pharmaceuticals, Inc. - Preclinical, 2014 11
Aerie Pharmaceuticals, Inc. - Pipeline by Target, 2014 15
Aerie Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 16
Aerie Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 17
Aerie Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 18
Aerie Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 19
Aerie Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 22
Aerie Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 23
Aerie Pharmaceuticals, Inc., Other Locations 24 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify